


Please type a plus sign inside this box 

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number		09/421,545
Filing Date		October 20, 1999
First Named Inventor		Dr. Gregory R. MUNDY
Group Art Unit		1651
Examiner Name		R. Gitomer
Total Number of Pages in This Submission	3	Attorney Docket Number
		432722002621

## ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Summary of Interview of June 19, 2003 (2 pages);
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Return Receipt Postcard.
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	MORRISON & FOERSTER LLP Laurie L. Hill - 51,804
Signature	
Date	7-2-03

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7-2-03

Signature:  (Marian L. Christopher)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 2, 2003

Signature:

*Marian L. Christopher*  
(Marian L. Christopher)

Docket No.: 432722002621  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Gregory R. MUNDY, et al

Examiner: R. Gitomer

Application No.: 09/421,545

Group Art Unit: 1651

Filed: October 20, 1999

For: INHIBITORS OF PROTEASOMAL ACTIVITY  
FOR STIMULATING BONE AND HAIR  
GROWTH

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900

SUMMARY OF INTERVIEW OF JUNE 19, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

On June 19, 2003, a telephone interview was held in the above application by Examiner Michael Wityshyn and Applicants' attorney, Laurie L. Hill.

Applicants gratefully acknowledge the time and effort of Michael Wityshyn in his review of the file history of the instant application. The interview with Dr. Wityshyn was very productive and helpful to Applicants.


The substance of the interview is summarized herewith. Attorney for Applicants contacted Dr. Wityshyn requested his review of the file history with regards to the outstanding written description and enablement rejections under 35 U.S.C. § 112. After review of the file, Dr. Wityshyn withdrew the written description and enablement rejections in view of the arguments and evidence submitted by Applicants. Dr. Wityshyn also indicated that the obviousness type double

sd-153660

patenting rejection would be maintained until the sufficiency of the copy of the terminal disclaimer is determined. Finally, Dr. Wityshyn indicated several formal matters requiring Action from Applicants, including (1) amending the specification to include the term "peptidyl aldehyde", (2) amending the specification with regards to the amino acid sequences to provide the required SEQ ID NOs, and (3) filing a substitute declaration that includes Rossini full name and indicates the date of amendment of the specification. According to Dr. Wityshyn, if the terminal disclaimer is sufficient and no prior is discovered in the IDS 1449 forms, a Quayle action will be sent from the Office directed to the formal matters discussed above.

Dated: July 2, 2003

Respectfully submitted,

By   
Laurie L. Hill, Ph.D.

Registration No.: 51,804  
MORRISON & FOERSTER LLP  
3811 Valley Centre, Suite 500  
San Diego, California 92130

Telephone: (858) 720-7955  
Facsimile: (858) 720-5125  
Attorneys for Applicant